We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Illumina Announces Collaboration with top Five Pharmaceutical Companies

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Illumina, Inc. has announced a multi-million dollar agreement with one of the top five pharmaceutical companies for the purchase and installation of a multi-component genetic analysis system.

Depending on the Illumina arrays being processed, this system will be capable of generating over 45 million genotypes per day, and will represent a core support facility for the company's global research teams.

The Illumina genetic analysis system is designed to run both genotyping and gene expression applications and will include a number of scanners and robotic components for automated sample and array processing.

An initial project involving 3,200 samples will be run using Illumina's Infinium® Assay and the HumanHap650Y BeadChip, which provide genomic coverage and the per-marker information content of any whole-genome genotyping arrays.

"We are excited that the pharmaceutical industry is adopting large-scale genotyping and that Illumina is at the forefront of this new technology," said Jay Flatley, Illumina President and CEO.

"This demonstrates that genotyping has become a robust discovery method and is now poised to move more routinely into clinical development to support pharmacogenomic and predictive diagnostic applications."